-+ 0.00%
-+ 0.00%
-+ 0.00%

MERCK AND MODERNA ANNOUNCE PHASE 3 INTERPATH-001 TRIAL OF INTISMERAN AUTOGENE PLUS KEYTRUDA® MET ENDPOINTS OF RECURRENCE-FREE SURVIVAL (RFS) AND DISTANT METASTASIS-FREE SURVIVAL (DMFS) IN PATIENTS WITH COMPLETELY RESECTED STAGE IIB-IV MELANOMA

路透·08/19/2026 10:45:00

登錄查看新聞詳情